Genmab — Januar 2026
-
the EPCORE CLL-1 completion dates moved forward by 1 1/2 year, maybe due to fast recruitment? https://clinicaltrials.gov/study/NCT04623541?tab=history&a=34&b=35&compareMode=sideBySide#version-content-panel really curious if CLL will be pursued with Epco...
-
RAINFOL-04 starts recruiting https://clinicaltrials.gov/study/NCT07225270?tab=history&a=5&b=6#version-content-panel
-
Genmab accelerer arbejdet med AI - indgår partnerskab med Anthropic https://proinvestor.com/investornyt/1400587/genmab-accelerer-arbejdet-med-ai-indgar-partnerskab-med-anthropic
-
Den AI meddelelse er lidt en tynd kop te. R&D har noget at bevise og jeg forventer mig mere af deres interne data mining end AI https://claude.com/solutions/life-sciences
-
more on UBS - believes Genmab has the potential to transform its equity story in 2026, naming it as the firm’s top pick for European biotech in 2026 https://www.investing.com/news/analyst-ratings/ubs-raises-genmab-stock-price-target-to-dkk2750-on-pipeline-potential-93CH-4436366
-
Her opdateret kanal. Trenden er stadig op. Solgte 50% af mine Genmab igår i kurs 2200 området. Forventer at kunne købe under 2100 senere. Ser +2500 omkring April / Maj - 2026
Tryk på billed for af gøre større https://proinvestor.com/boards/125146/$/130622
-
Genmab in the
Morningstar Top European Stock Picks for Q1 2026 https://global.morningstar.com/en-nd/stocks/best-european-stocks-q1-2026-our-top-picks-by-sector -
for the Dutch - De belofte van petosemtamab voor gevorderde of gemetastaseerde hoofd-halskanker https://www.mednet.nl/nieuws/de-belofte-van-petosemtamab-voor-gevorderde-of-gemetastaseerde-hoofd-halskanker/
-
Det tidligere modstandsområde omkring 2.080–2.100 er nu blevet vendt til støtte, hvilket er et klassisk “breakout–pullback–continuation”-mønster. Markedet accepterer altså højere prisniveauer. Bevægelsen er desuden kontrolleret og kursen ligger i den øvre del af sit handelsinterval uden at være ekstremt overstrakt i forhold til Bollinger-båndene.
-
From antibody science to patient impact: Genmab’s next phase - Sponsored Insight
-
RYBREVANT
(amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer https://www.jnj.com/media-center/press-releases/rybrevant-amivantamab-vmjw-longer-term-results-show-promising-and-durable-responses-in-difficult-to-treat-colorectal-cancer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind